EC Number | Activating Compound | Comment | Organism | Structure |
---|---|---|---|---|
2.7.11.18 | Calmodulin | required | Mus musculus |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
2.7.11.18 | ML-7 | - |
Mus musculus |
EC Number | Metals/Ions | Comment | Organism | Structure |
---|---|---|---|---|
2.7.11.18 | Ca2+ | dependent on | Mus musculus | |
2.7.11.18 | Mg2+ | dependent on | Mus musculus | |
2.7.11.18 | Zn2+ | dependent on | Mus musculus |
EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.7.11.18 | ATP + [myosin light chain] | Mus musculus | - |
ADP + [myosin light chain] phosphate | - |
? | |
2.7.11.18 | ATP + [myosin light chain] | Mus musculus CF-1 | - |
ADP + [myosin light chain] phosphate | - |
? |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
2.7.11.18 | Mus musculus | Q3UIZ8 | - |
- |
2.7.11.18 | Mus musculus CF-1 | Q3UIZ8 | - |
- |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
2.7.11.18 | egg | ovulated metaphase II eggs | Mus musculus | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
2.7.11.18 | ATP + [myosin light chain] | - |
Mus musculus | ADP + [myosin light chain] phosphate | - |
? | |
2.7.11.18 | ATP + [myosin light chain] | - |
Mus musculus CF-1 | ADP + [myosin light chain] phosphate | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
2.7.11.18 | MLCK | - |
Mus musculus |
2.7.11.18 | myosin light chain kinase | - |
Mus musculus |
EC Number | Cofactor | Comment | Organism | Structure |
---|---|---|---|---|
2.7.11.18 | ATP | - |
Mus musculus |
EC Number | General Information | Comment | Organism |
---|---|---|---|
2.7.11.18 | malfunction | in meiosis I, MLCK inhibition and other myosin perturbations impair spindle migration and first polar body emission. Inhibition of the MEK1/2-MAPK pathway with U0126 leads to reduced levels of phosphorylated myosin-regulatory light chain (pMRLC) and causes a reduction in cortical tension, effects that are mimicked by treatment with the myosin light chain kinase (MLCK) inhibitor ML-7. MAPK or MLCK inhibition induces loss of normal cortical spindle localization or parthenogenetic egg activation. This parthenogenesis is dependent on cytosolic and extracellular calcium and can be rescued by hyperloading eggs with zinc, suggesting that these effects of inhibition of MLCK or the MAPK pathway are linked with dysregulation of ion homeostasis, overview | Mus musculus |
2.7.11.18 | metabolism | MAPK3/1 (ERK1/2, EC 2.7.11.24) and myosin light chain kinase in mammalian eggs affect myosin-II function and regulate the metaphase II state in a calcium- and zinc-dependent manner. Vertebrate eggs are arrested at metaphase of meiosis II, a state classically known as cytostatic factor arrest. Maintenance of this arrest until the time of fertilization and then fertilizationinduced exit from metaphase II are crucial for reproductive success, overview | Mus musculus |
2.7.11.18 | physiological function | MLCK phosphorylates myosin regulatory light chain (MRLC, also known as MYL9), which enables myosin-II organization into bipolar thick filaments | Mus musculus |